Literature DB >> 12000654

Measles in suburban Khartoum: an epidemiological and clinical study.

S A Ibrahim1, O M Mustafa, M M Mukhtar, E A Saleh, H S El Mubarak, A Abdallah, A M El-Hassan, A D M E Osterhaus, J Groen, R L De Swart, E E Zijlstra.   

Abstract

Clinical and epidemiological data were collected from 187 clinically diagnosed measles patients in Haj Yousif area, suburban Khartoum. Laboratory tests confirmed the diagnosis in 141 (75%) of the cases, but demonstrated that in 46 (25%) patients the clinical symptoms were not caused by an acute measles virus (MV) infection. According to their vaccination card, 59% of the laboratory-confirmed measles cases had been vaccinated for measles. Compared with non-measles rash disease cases, confirmed measles cases more often had severe illness (P < 0.0001), were dehydrated (P=0.01) at presentation and less likely to recover without complications [OR 0.19 (95% CI 0.09, 0.39)]. There was no difference in death rate (P=0.20). Underweight [weight-for-age Z score (WAZ) <or= -2 SD] was an independent predictor of recovery with complications [OR 0.4 (95% CI 0.2, 0.99)]. Severe measles cases (those who developed diarrhoea, pneumonia, otitis media, encephalitis or haemorrhagic rash) had similar vaccination rates and time intervals since vaccination as uncomplicated measles cases. Although severe measles had lower WAZ-scores (P=0.004), none of the nutritional parameters studied were predictive of outcome. Mortality was higher in the severe measles group [OR 8.8 (95% CI 1.7, 85.2)]. In 11 of 141 confirmed measles cases serological evidence of a recent infection with another virus was found, most commonly varicella zoster virus and dengue virus; spotted fever and rubella were among the most frequent diagnoses in 17 of 47 cases of the non-measles cases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12000654     DOI: 10.1046/j.1365-3156.2002.00884.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  7 in total

Review 1.  Emerging diseases: measles.

Authors:  Martin O Ota; William J Moss; Diane E Griffin
Journal:  J Neurovirol       Date:  2005-10       Impact factor: 2.643

2.  Measles virus-specific antibody levels in Sudanese infants: a prospective study using filter-paper blood samples.

Authors:  S A Ibrahim; A Abdallah; E A Saleh; A D M E Osterhaus; R L De Swart
Journal:  Epidemiol Infect       Date:  2006-02       Impact factor: 2.451

3.  Early target cells of measles virus after aerosol infection of non-human primates.

Authors:  Ken Lemon; Rory D de Vries; Annelies W Mesman; Stephen McQuaid; Geert van Amerongen; Selma Yüksel; Martin Ludlow; Linda J Rennick; Thijs Kuiken; Bertus K Rima; Teunis B H Geijtenbeek; Albert D M E Osterhaus; W Paul Duprex; Rik L de Swart
Journal:  PLoS Pathog       Date:  2011-01-27       Impact factor: 6.823

Review 4.  Dengue in the Middle East and North Africa: A Systematic Review.

Authors:  John M Humphrey; Natalie B Cleton; Chantal B E M Reusken; Marshall J Glesby; Marion P G Koopmans; Laith J Abu-Raddad
Journal:  PLoS Negl Trop Dis       Date:  2016-12-07

Review 5.  Available studies fail to provide strong evidence of increased risk of diarrhea mortality due to measles in the period 4-26 weeks after measles rash onset.

Authors:  Bianca D Jackson; Robert E Black
Journal:  BMC Public Health       Date:  2017-11-07       Impact factor: 3.295

Review 6.  Re-Emerging Vaccine-Preventable Diseases in War-Affected Peoples of the Eastern Mediterranean Region-An Update.

Authors:  Rasha Raslan; Skye El Sayegh; Sana Chams; Nour Chams; Angelo Leone; Inaya Hajj Hussein
Journal:  Front Public Health       Date:  2017-10-25

7.  Dengue and chikungunya seroprevalence among Qatari nationals and immigrants residing in Qatar.

Authors:  John M Humphrey; Enas S Al-Absi; Munia M Hamdan; Sara S Okasha; Diyna M Al-Trmanini; Hend G El-Dous; Soha R Dargham; John Schieffelin; Laith J Abu-Raddad; Gheyath K Nasrallah
Journal:  PLoS One       Date:  2019-01-31       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.